NDC codes

FDA NDC Directory
Product NDC (as listed)29300-460Labeler and product segments. Claims need a package NDC.
Product NDC at billing width29300-0460Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
29300-460-0129300046001100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (29300-460-01)Marketed from Feb 1, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Guanfacine
Generic name (nonproprietary)
guanfacine
Active ingredients
Guanfacine hydrochloride — 1 mg/1
Dosage form
Tablet, Extended release
Route
Oral
Product type
Prescription drug
Marketing category
ANDA — Abbreviated New Drug Application (generic)Application ANDA 219033
Marketing start
Listing expires
Other FDA classes
Adrenergic alpha2-Agonists (Mechanism)
Identifiers
Product ID 29300-460_02271fb1-d7ad-49cb-a6a4-622e458e5db7SPL ID 02271fb1-d7ad-49cb-a6a4-622e458e5db7SPL set ID f4e3c976-8811-4388-92b3-d248d705f8b1RxCUI 862006, 862013, 862019, 862025UNII PML56A160OUPC 0329300460018, 0329300463019, 0329300461015
Pharmacologic class
Central alpha-2 Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N429300046001 followed by a unit qualifier and the quantity

Package 29300-0460-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies ( 14 )]. Guanfacine extended-release tablets are central alpha 2 A-adrenergic receptor agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications ( 1 , 14 ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 219033

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 219033
ProductStrengthForm · routeLabelerProduct NDC
GuanfacineGuanfacine hydrochloride 3 mg/1Tablet, Extended releaseOralUnichem Pharmaceuticals (USA), Inc.29300-462
GuanfacineGuanfacine hydrochloride 2 mg/1Tablet, Extended releaseOralUnichem Pharmaceuticals (USA), Inc.29300-461
GuanfacineGuanfacine hydrochloride 4 mg/1Tablet, Extended releaseOralUnichem Pharmaceuticals (USA), Inc.29300-463
GuanfacineGuanfacine hydrochloride 2 mg/1Tablet, Extended releaseOralREMEDYREPACK INC.70518-4675
GuanfacineGuanfacine hydrochloride 1 mg/1Tablet, Extended releaseOralREMEDYREPACK INC.70518-4539

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in